Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SYNACORT.
FLUDROCORTISONE ACETATE vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
0.1 mg orally once daily, range 0.05-0.2 mg/day
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid